Satish C. Tripathi
Profile
Satish C.
Tripathi worked as Vice President-Global Regulatory Affairs at Selecta Biosciences, Inc., Senior VP-Global Regulatory Affairs at IVERIC bio, Inc., and Vice President-Global Regulatory Affairs at Novartis Gene Therapies, Inc. He holds a doctorate degree from the University of Glasgow, a graduate degree from The Trustees of Columbia University in The City of New York, a graduate degree from Jiwaji University, and an undergraduate degree from the University of Barkatullah.
Former positions of Satish C. Tripathi
| Companies | Position | End |
|---|---|---|
| CARTESIAN THERAPEUTICS, INC. | General Counsel | - |
| AVEXIS INC | General Counsel | - |
| IVERIC BIO, INC. | General Counsel | - |
Training of Satish C. Tripathi
| Jiwaji University | Graduate Degree |
| University of Barkatullah | Graduate Degree |
| University of Glasgow | Doctorate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 3 |
|---|---|
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Stock Market
- Insiders
- Satish C. Tripathi